Potential Pitfall: Positive Follicular Lymphoma on [ 68 Ga]-PSMA-11 PET/CT for Prostate Cancer Staging.
1/5 보강
Prostate-specific membrane antigen (PSMA)-targeted PET agents are a mainstay in staging high-risk prostate cancer.
APA
Heniche Y, Abikhzer G, McPherson V (2025). Potential Pitfall: Positive Follicular Lymphoma on [ 68 Ga]-PSMA-11 PET/CT for Prostate Cancer Staging.. Clinical nuclear medicine, 50(11), 1053-1054. https://doi.org/10.1097/RLU.0000000000006062
MLA
Heniche Y, et al.. "Potential Pitfall: Positive Follicular Lymphoma on [ 68 Ga]-PSMA-11 PET/CT for Prostate Cancer Staging.." Clinical nuclear medicine, vol. 50, no. 11, 2025, pp. 1053-1054.
PMID
40694857 ↗
Abstract 한글 요약
Prostate-specific membrane antigen (PSMA)-targeted PET agents are a mainstay in staging high-risk prostate cancer. Nevertheless, PSMA expression is not exclusive to prostate cancer and is present in various neoplasms and inflammatory conditions. We report a case of biopsy-proven follicular lymphoma positive on PSMA PET/CT originally performed for staging of prostate cancer in a 66-year-old patient. This case highlights the potential pitfall of lymphoma mimicking prostate cancer nodal metastasis on PSMA PET/CT and the importance of careful evaluation of distribution and uptake of lymph nodes when assessing PSMA PET/CT studies to distinguish lymphoma from prostate cancer metastases.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.